Alberta Investment Management Corp Makes New $7.51 Million Investment in Boston Scientific Corporation $BSX

Alberta Investment Management Corp bought a new stake in Boston Scientific Corporation (NYSE:BSX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 78,760 shares of the medical equipment provider’s stock, valued at approximately $7,510,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in BSX. FWL Investment Management LLC bought a new stake in Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the fourth quarter valued at about $26,000. Colonial Trust Co SC grew its position in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares during the last quarter. Bangor Savings Bank raised its stake in Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund bought a new position in shares of Boston Scientific in the fourth quarter worth about $29,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 9,800 shares of company stock valued at $554,012 over the last ninety days. 0.34% of the stock is owned by company insiders.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $46.92 on Wednesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52 week low of $45.99 and a 52 week high of $109.50. The firm has a market cap of $69.74 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56. The firm’s fifty day moving average is $55.74 and its 200-day moving average is $74.02.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has authorized a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Canaccord Genuity Group lowered their price objective on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Truist Financial dropped their price target on Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, June 4th. Jefferies Financial Group reduced their price objective on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Finally, Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $85.08.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.